Hikma Pharmaceuticals

Mid-term outlook downgrade might not be as bad as it appears

07/11/25 -"All segments performed decently in Q3, though the markets were spooked by Hikma’s mid-term outlook downgrade. Operational delays at the Bedford manufacturing facility, an increasing R&D ..."

PDF page sample
Pages
53
Language
English
Published on
07/11/25
Download
You may also be interested by these reports :
07/11/25
Genmab’s Q3 results surpassed the street’s expectations, driven by robust performance across most offerings, resulting in solid profitability ...
07/11/25
All segments performed decently in Q3, though the markets were spooked by Hikma’s mid-term outlook downgrade. Operational delays at the Bedford ...
07/11/25
Novonesis delivered a good Q3 2025, with revenue and adjusted EBITDA beating consensus. Organic sales growth of 6% was driven by broad-based volume ...
06/11/25
The Q3 results surpassed expectations, backed by strong performance from Oncology, Respiratory & Immunology, and Rare Disease medicines. Now, the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO